#USA #San Diego #Allergan Aesthetics #BOTOX Cosmetic #ASDS 2026

Allergan Aesthetics Presents Transformative Research at ASDS 2026

Allergan Aesthetics, a part of AbbVie, will be presenting nine new abstracts during the upcoming American Society for Dermatologic Surgery (ASDS) Annual Meeting from November 5 to 8, 2026, in San Diego. This year's presentations emphasize the significant evolution in aesthetic care, particularly in response to changing patient needs following medical weight loss strategies.

A key focus of the research is derived from Phase 4 studies that explore the psychosocial aspects and satisfaction levels of patients undergoing aesthetic treatments while using glucagon-like peptide-1 (GLP-1) medication for weight management. Dr. Darin Messina, Senior Vice President at AbbVie, expressed the importance of understanding patients' evolving requirements and maintaining robust scientific research to guide aesthetic practices. He states, “Advancing aesthetic medicine starts with understanding patients' evolving needs and generating the scientific evidence to keep pace.”

Insights into Patient Needs

Research findings illustrate that medical weight loss brings about aesthetic concerns that are not limited to issues of facial volume or skin texture. Dr. Joely Kaufman-Janette, a board-certified dermatologist, pointed out that by aligning patient satisfaction and psychosocial well-being with physical changes, practitioners can address the full spectrum of patient needs and provide customized care during their aesthetic journeys.

Among the notable presentations will be an analysis titled "Similar Clinical Outcomes in Glabellar Line Severity and Brow Position Following TrenibotE and OnabotA Treatment: A Digital Image Analysis,” scheduled for the Cosmetic Oral Abstract Presentations Top Ten session. Clinicians will utilize objective imaging to better quantify results and complement visual assessments.

Expert Panel Discussion

To further enrich the dialogue at ASDS 2026, Allergan Aesthetics will host an expert panel discussion entitled “The Aesthetics Evolution Inside the Changing Consumer Landscape” on November 5. Moderated by Dr. Tiffany Libby, this panel will feature insights from leading dermatologists, addressing evolving consumer expectations and clarifying prevalent misconceptions about medical weight loss in aesthetic treatments. This panel aims to provide healthcare providers with meaningful contextual data to improve patient interactions and treatment outcomes.

Multimodal Treatment Initiatives

Allergan's presentations will also delve into the innovation surrounding multimodal aesthetic treatments designed for diverse patient demographics. Presentations will highlight strategies to enhance skin quality using topical human fibroblast-derived exosome serums alongside in-office procedures including radiofrequency microneedling and non-ablative laser techniques. The research aims to unravel how different treatment sequences may impact overall patient experiences and results, particularly in body contouring procedures combining cryolipolysis and electromagnetic muscle stimulation for abdominal enhancement.

Conclusion

With these exciting research developments, Allergan Aesthetics continues to showcase its dedication to improving aesthetic outcomes and enhancing patient journeys. As the industry evolves, engaging with these insights will not only help practitioners meet the unique needs of their patients but also equip them to offer personalized care resonating with contemporary aesthetic aspirations. The comprehensive research being presented at ASDS 2026 marks a pivotal moment in aesthetic medicine, aiming to redefine how clinicians approach patient care in a changing landscape of aesthetic preferences and medical advancements.